nach oben

Journal of Radiation Oncology

Erschienen in:

01.03.2016 | Review

Radiation emergencies: radiation-related brain and lung injury

verfasst von: Matthew S. Ning, Joseph M. Kaminski, Darko Pucar, Eric T. Shinohara

Erschienen in: Journal of Radiation Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The advent of modern radiation techniques, such as intensity modulated and stereotactic ablative radiation therapy, has permitted increasingly accurate delivery of radiation, with ability to shape distribution of dose specifically to the tumor. These techniques limit dose to surrounding normal tissue in an effort to reduce toxicity; however, despite such improvements, potentially serious side effects related to treatment may occur, requiring urgent management.

Objective

Radiation-related brain or lung injury in previously irradiated patients may present in the acute or late post-treatment setting. Patients initially present with non-specific symptoms associated with the organ in question, representing a diagnostic challenge in the emergency room. Here, we review potential complications that may occur following radiation therapy to two commonly treated sites: brain and thorax.

Conclusions

We provide a guideline of the presentation, diagnosis, and management of these complications to function as a useful resource for healthcare providers. Furthermore, we review thedosimetric and volumetric parameters associated with such adverse events.

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29. doi:10.3322/caac.21208 CrossRefPubMed

Lee AW, Foo W, Chappell R et al (1998) Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 40:35–42CrossRefPubMed

Telera S, Fabi A, Pace A et al (2013) Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease. J Neurooncol 113:313–325. doi:10.1007/s11060-013-1120-8 CrossRefPubMed

Chao ST, Ahluwalia MS, Barnett GH et al (2013) Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int J Radiat Oncol Biol Phys 87:449–457. doi:10.1016/j.ijrobp.2013.05.015 CrossRefPubMed

Eichler AF, Chung E, Kodack DP et al (2011) The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 8:344–356. doi:10.1038/nrclinonc.2011.58 PubMedPubMedCentral

Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5–14. doi:10.1007/s11060-004-8093-6 CrossRefPubMed

Barnholtz-Sloan JS, Sloan AE, Davis FG et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol Off J Am Soc Clin Oncol 22:2865–2872. doi:10.1200/JCO.2004.12.149 CrossRef

Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698–2705CrossRefPubMed

Stockham AL, Ahluwalia M, Reddy CA et al (2013) Results of a questionnaire regarding practice patterns for the diagnosis and treatment of intracranial radiation necrosis after SRS. J Neurooncol 115:469–475. doi:10.1007/s11060-013-1248-6 CrossRefPubMed

10.

Sheline GE, Wara WM, Smith V (1980) Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 6:1215–1228CrossRefPubMed

11.

Werner-Wasik M, Rudoler S, Preston PE et al (1999) Immediate side effects of stereotactic radiotherapy and radiosurgery. Int J Radiat Oncol Biol Phys 43:299–304CrossRefPubMed

12.

Vecht CJ, Hovestadt A, Verbiest HB et al (1994) Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 44:675–680CrossRefPubMed

13.

Ryan J (2000) Radiation somnolence syndrome. J Pediatr Oncol Nurs Off J Assoc Pediatr Oncol Nurs 17:50–53CrossRef

14.

Griebel M, Friedman HS, Halperin EC et al (1991) Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma. Med Pediatr Oncol 19:182–186CrossRefPubMed

15.

Fiegler W, Langer M, Scheer M, Kazner E (1986) Reversible computed tomographic changes following brain tumor irradiation induced by the “early-delayed reaction” after radiation. Radiol 26:206–209

16.

Watne K, Hager B, Heier M, Hirschberg H (1990) Reversible oedema and necrosis after irradiation of the brain. Diagnostic procedures and clinical manifestations. Acta Oncol Stockh Swed 29:891–895CrossRef

17.

Brandsma D, Stalpers L, Taal W et al (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461. doi:10.1016/S1470-2045(08)70125-6 CrossRefPubMed

18.

Chamberlain MC, Glantz MJ, Chalmers L et al (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81–83. doi:10.1007/s11060-006-9241-y CrossRefPubMed

19.

Shah R, Vattoth S, Jacob R et al (2012) Radiation necrosis in the brain: imaging features and differentiation from tumor recurrence. Radiogr Rev Publ Radiol Soc N Am Inc 32:1343–1359. doi:10.1148/rg.325125002

20.

Shaw E, Scott C, Souhami L et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05. Int J Radiat Oncol Biol Phys 47:291–298CrossRefPubMed

21.

Shaw E, Arusell R, Scheithauer B et al (2002) Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol 20:2267–2276CrossRef

22.

Kumar AJ, Leeds NE, Fuller GN et al (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217:377–384. doi:10.1148/radiology.217.2.r00nv36377 CrossRefPubMed

23.

Mayer R, Sminia P (2008) Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys 70:1350–1360. doi:10.1016/j.ijrobp.2007.08.015 CrossRefPubMed

24.

McPherson CM, Warnick RE (2004) Results of contemporary surgical management of radiation necrosis using frameless stereotaxis and intraoperative magnetic resonance imaging. J Neurooncol 68:41–47CrossRefPubMed

25.

Flickinger JC, Kondziolka D, Maitz AH, Lunsford LD (1998) Analysis of neurological sequelae from radiosurgery of arteriovenous malformations: how location affects outcome. Int J Radiat Oncol Biol Phys 40:273–278CrossRefPubMed

26.

Ruben JD, Dally M, Bailey M et al (2006) Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65:499–508. doi:10.1016/j.ijrobp.2005.12.002 CrossRefPubMed

27.

Lee AWM, Kwong DLW, Leung SF et al (2002) Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys 53:75–85CrossRefPubMed

28.

Murray KJ, Scott C, Greenberg HM et al (1997) A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 39:571–574CrossRefPubMed

29.

Lawrence YR, Li XA, el Naqa I et al (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76:S20–27. doi:10.1016/j.ijrobp.2009.02.091 CrossRefPubMedPubMedCentral

30.

Varlotto JM, Flickinger JC, Niranjan A et al (2003) Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 57:452–464CrossRefPubMed

31.

Voges J, Treuer H, Sturm V et al (1996) Risk analysis of linear accelerator radiosurgery. Int J Radiat Oncol Biol Phys 36:1055–1063CrossRefPubMed

32.

Flickinger JC, Kondziolka D, Pollock BE et al (1997) Complications from arteriovenous malformation radiosurgery: multivariate analysis and risk modeling. Int J Radiat Oncol Biol Phys 38:485–490CrossRefPubMed

33.

Korytko T, Radivoyevitch T, Colussi V et al (2006) 12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors. Int J Radiat Oncol Biol Phys 64:419–424. doi:10.1016/j.ijrobp.2005.07.980 CrossRefPubMed

34.

Blonigen BJ, Steinmetz RD, Levin L et al (2010) Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 77:996–1001. doi:10.1016/j.ijrobp.2009.06.006 CrossRefPubMed

35.

Minniti G, Clarke E, Lanzetta G et al (2011) Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol Lond Engl 6:48. doi:10.1186/1748-717X-6-48 CrossRef

36.

Corn BW, Yousem DM, Scott CB et al (1994) White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83–02). Cancer 74:2828–2835CrossRefPubMed

37.

Sause WT, Scott C, Krisch R et al (1993) Phase I/II trial of accelerated fractionation in brain metastases RTOG 85–28. Int J Radiat Oncol Biol Phys 26:653–657CrossRefPubMed

38.

McDonald S, Rubin P, Phillips TL, Marks LB (1995) Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 31:1187–1203. doi:10.1016/0360-3016(94)00429-O CrossRefPubMed

39.

Lingos TI, Recht A, Vicini F et al (1991) Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 21:355–360CrossRefPubMed

40.

Chakravarthy A, Johnson D, Choy H (1999) The role of radiation, with or without chemotherapy, in the management of NSCLC. Oncol Williston Park N 13:93–100

41.

Hochstrasser A, Benz G, Joerger M et al (2012) Interstitial pneumonitis after treatment with pemetrexed: a rare event? Chemotherapy 58:84–88. doi:10.1159/000336131 CrossRefPubMed

42.

Vahid B, Marik PE (2008) Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133:528–538. doi:10.1378/chest.07-0851 CrossRefPubMed

43.

Pang Q, Wei Q, Xu T et al (2013) Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 85:1332–1339. doi:10.1016/j.ijrobp.2012.10.011 CrossRefPubMed

44.

Jiang Z-Q, Yang K, Komaki R et al (2012) Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys 83:332–339. doi:10.1016/j.ijrobp.2011.06.1963 CrossRefPubMed

45.

Kwa SL, Lebesque JV, Theuws JC et al (1998) Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42:1–9CrossRefPubMed

46.

Ikezoe J, Takashima S, Morimoto S et al (1988) CT appearance of acute radiation-induced injury in the lung. AJR Am J Roentgenol 150:765–770. doi:10.2214/ajr.150.4.765 CrossRefPubMed

47.

Keidar Z, Haim N, Guralnik L et al (2004) PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med Off Publ Soc Nucl Med 45:1640–1646

48.

Nakajima N, Sugawara Y, Kataoka M et al (2013) Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. Ann Nucl Med 27:261–270. doi:10.1007/s12149-012-0682-4 CrossRefPubMed

49.

Morgan GW, Breit SN (1995) Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys 31:361–369. doi:10.1016/0360-3016(94)00477-3 CrossRefPubMed

50.

Nakayama Y, Makino S, Fukuda Y et al (1996) Activation of lavage lymphocytes in lung injuries caused by radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 34:459–467CrossRefPubMed

51.

Robnett TJ, Machtay M, Vines EF et al (2000) Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 48:89–94CrossRefPubMed

52.

Abratt RP, Morgan GW, Silvestri G, Willcox P (2004) Pulmonary complications of radiation therapy. Clin Chest Med 25:167–177. doi:10.1016/S0272-5231(03)00126-6 CrossRefPubMed

53.

Wohl ME, Griscom NT, Traggis DG, Jaffe N (1975) Effects of therapeutic irradiation delivered in early childhood upon subsequent lung function. Pediatrics 55:507–516PubMed

54.

Lopez Guerra JL, Gomez D, Zhuang Y et al (2012) Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 83:1573–1579. doi:10.1016/j.ijrobp.2011.10.065 CrossRefPubMed

55.

Borst GR, De Jaeger K, Belderbos JSA et al (2005) Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with long-term disease-free survival. Int J Radiat Oncol Biol Phys 62:639–644. doi:10.1016/j.ijrobp.2004.11.029 CrossRefPubMed

56.

Marks LB, Bentzen SM, Deasy JO et al (2010) Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 76:S70–76. doi:10.1016/j.ijrobp.2009.06.091 CrossRefPubMedPubMedCentral

57.

Mazeron R, Etienne-Mastroianni B, Pérol D et al (2010) Predictive factors of late radiation fibrosis: a prospective study in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 77:38–43. doi:10.1016/j.ijrobp.2009.04.019 CrossRefPubMed

58.

Kong F-M, Hayman JA, Griffith KA et al (2006) Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65:1075–1086. doi:10.1016/j.ijrobp.2006.01.051 CrossRefPubMed

59.

Palma DA, Senan S, Tsujino K et al (2013) Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 85:444–450. doi:10.1016/j.ijrobp.2012.04.043 CrossRefPubMedPubMedCentral

60.

Yom SS, Liao Z, Liu HH et al (2007) Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68:94–102. doi:10.1016/j.ijrobp.2006.12.031 CrossRefPubMed

61.

Sura S, Gupta V, Yorke E et al (2008) Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol J Eur Soc Ther Radiol Oncol 87:17–23. doi:10.1016/j.radonc.2008.02.005 CrossRef

62.

Shi A, Zhu G, Wu H et al (2010) Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy. Radiat Oncol Lond Engl 5:35. doi:10.1186/1748-717X-5-35 CrossRef

63.

Baker R, Han G, Sarangkasiri S et al (2013) Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys 85:190–195. doi:10.1016/j.ijrobp.2012.03.041 CrossRefPubMed

64.

Barriger RB, Forquer JA, Brabham JG et al (2012) A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 82:457–462. doi:10.1016/j.ijrobp.2010.08.056 CrossRefPubMed

65.

Borst GR, Ishikawa M, Nijkamp J et al (2009) Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol J Eur Soc Ther Radiol Oncol 91:307–313. doi:10.1016/j.radonc.2009.02.003 CrossRef

66.

Bongers EM, Botticella A, Palma DA et al (2013) Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs. Radiother Oncol J Eur Soc Ther Radiol Oncol 109:95–99. doi:10.1016/j.radonc.2013.10.011 CrossRef

67.

Chang JY, Li Q-Q, Xu Q-Y et al (2014) Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone.”. Int J Radiat Oncol Biol Phys 88:1120–1128. doi:10.1016/j.ijrobp.2014.01.022 CrossRefPubMed

68.

Guckenberger M, Heilman K, Wulf J et al (2007) Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol J Eur Soc Ther Radiol Oncol 85:435–442. doi:10.1016/j.radonc.2007.10.044 CrossRef

69.

Matsuo Y, Shibuya K, Nakamura M et al (2012) Dose–volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 83:e545–549. doi:10.1016/j.ijrobp.2012.01.018 CrossRefPubMed

70.

Yamashita H, Nakagawa K, Nakamura N et al (2007) Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol Lond Engl 2:21. doi:10.1186/1748-717X-2-21 CrossRef

71.

Guckenberger M, Baier K, Polat B et al (2010) Dose–response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol 97:65–70. doi:10.1016/j.radonc.2010.04.027 CrossRef

72.

Ricardi U, Filippi AR, Guarneri A et al (2009) Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy. Acta Oncol Stockh Swed 48:571–577. doi:10.1080/02841860802520821 CrossRef

73.

Hernando ML, Marks LB, Bentel GC et al (2001) Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51:650–659CrossRefPubMed

Titel: Radiation emergencies: radiation-related brain and lung injury
verfasst von: Matthew S. Ning
Joseph M. Kaminski
Darko Pucar
Eric T. Shinohara
Publikationsdatum: 01.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Radiation Oncology / Ausgabe 1/2016
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-015-0241-4

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Radiation emergencies: radiation-related brain and lung injury

Abstract

Background

Objective

Conclusions

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Objective

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Interval to biochemical failure is prognostic for distant metastases after salvage radiation therapy for prostate cancer

Re-implantation following suboptimal dosimetry in low-dose-rate prostate brachytherapy: technique for outpatient source insertion using local anesthesia

Low-dose aspirin mitigates acute radiation-induced genitourinary toxicity in patients with prostate adenocarcinoma

Role of thrombocytopenia in radiation-induced mortality and review of therapeutic approaches targeting platelet regeneration after radiation exposure

Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM)

Predictors of long-term survival for localized prostate cancer treated with high-dose IMRT stratified by NCCN 2015 guidelines in a community hospital setting

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Onkologie